5.37) <0.01 (4.99) 0.07 (5.37) <0.01 (22.46) 0.0Quizartinib web 5 0.01 0.36.16 (8.96) 9.69 (3.41)a Significance level of the w2 (or L-660711 sodium salt supplier Fisher’s exact) statistic for categorical variables and two-tailed t-test (or Wilcoxon’s rank sum test) for continuous variables.TABLE 4 Bivariate analysis of SLE patient characteristics and attitudes by CYC treatment preferencea variablesCharacteristic Number of subjects, n Race/ethnicity, n ( ) African-American White Medical insurance, n ( ) Without private With private Marital status, n ( ) Married Other (single, divorced, widowed) Perception of effectiveness, mean (S.D.) Perception of risk, mean (S.D.) Trust in physicians, mean (S.D.) Unwilling to receive CYC 39 31 (33.0) 8 (15.1) 24 (35.3) 15 (19.0) 11 28 17.44 11.72 35.79 (16.4) (35.0) (3.79) (2.33) (9.15) Willing to receive CYC 108 0.02 63 (67.0) 45 (84.9) 0.03 44 (64.7) 64 (81.0) 0.01 56 52 22.12 10.92 39.08 (83.6) (65.0) (3.82) (2.10) (7.64) P-valueb<0.001 0.05 0.a Among patients with no history of taking CYC. bSignificance level of the w2 (or Fisher's exact) statistic for categorical variables and two-tailed t-test (or Wilcoxon's rank sum test) for continuous variables.www.rheumatology.oxfordjournals.orgTreatment preferences in lupusTABLE 5 Logistic regression of willingness to receive CYC, with serial addition of sociodemographic variables, clinical context, personality traits and other patient beliefsaVariable, OR (95 CI) Race/ethnicity White African-American Incomeb Insurance Without private With private Marital status Not married Married Depression, CES-Dc Quartile 1 Quartile 2 Quartile 3 Quartile 4 Prayer efficacy No help Some help Much help Internal HLCc Quartile 1 Quartile 2 Quartile 3 Quartile 4 Perceived effectivenessb,c Trust in physiciansc Quartile 1 Quartile 2 Quartile 3 QuartileaModelModelModelModel1.00 0.36 (0.15, 0.86)1.00 0.32 (0.10, 1.00) 0.98 (0.59, 1.61) 1.00 1.50 (0.45, 4.97) 1.00 1.42 (0.57, 3.54)1.00 0.26 (0.08, 0.91) 1.11 (0.64, 1.93) 1.00 1.50 (0.42, 5.34) 1.00 1.34 (0.50, 3.61) 1.00 1.97 (0.63, 6.17) 5.73 (1.30, 25.17) 1.87 (0.48, 7.25) 1.00 0.94 (0.14, 6.45) 1.29 (0.19, 8.59) 1.00 1.04 (0.35, 3.08) 1.52 (0.43, 5.33) 3.09 (0.83, 11.52)1.00 0.27 (0.06, 1.26) 1.19 (0.60, 2.37) 1.00 1.27 (0.30, 5.43) 1.00 1.37(0.33, 5.59) 1.00 3.43 (0.78, 15.09) 9.83 (1.28, 75.25) 2.59 (0.41, 16.35) 1.00 0.61 (0.06, 6.23) 0.58 (0.06, 5.72) 1.00 0.79 1.47 1.68 1.(0.18, (0.30, (0.31, (1.23,3.38) 7.18) 9.10) 1.75)1.00 8.97 (1.85, 43.46) 1.66 (0.36, 7.68) 3.00 (0.59, 15.30)Among patients with no history of taking CYC. bPer unit difference. cHigher score indicates more of the concept being measured. HLC: health locus of control.Trust in physicians appears to be a more relevant factor in SLE patients' treatment preferences for CYC than race/ ethnicity. The significance of patient trust in physicians in determining patient preferences has been observed in other studies. In a study of Hispanic, African-American and white patients with knee OA, physician trust was a major determinant of racial and ethnic variation in joint replacement consideration by patients [9]. In a study of cardiac patients, patient level of medical mistrust was an independent predictor of patient satisfaction [17], which has been linked with patient compliance and utilization of health services [5]. Similarly, in a study of AfricanAmericans' perceptions of breast cancer treatment, mistrust of the medical establishment was a significant concern [24]. Racial/ethnic variations in treatment prefer.5.37) <0.01 (4.99) 0.07 (5.37) <0.01 (22.46) 0.05 0.01 0.36.16 (8.96) 9.69 (3.41)a Significance level of the w2 (or Fisher's exact) statistic for categorical variables and two-tailed t-test (or Wilcoxon's rank sum test) for continuous variables.TABLE 4 Bivariate analysis of SLE patient characteristics and attitudes by CYC treatment preferencea variablesCharacteristic Number of subjects, n Race/ethnicity, n ( ) African-American White Medical insurance, n ( ) Without private With private Marital status, n ( ) Married Other (single, divorced, widowed) Perception of effectiveness, mean (S.D.) Perception of risk, mean (S.D.) Trust in physicians, mean (S.D.) Unwilling to receive CYC 39 31 (33.0) 8 (15.1) 24 (35.3) 15 (19.0) 11 28 17.44 11.72 35.79 (16.4) (35.0) (3.79) (2.33) (9.15) Willing to receive CYC 108 0.02 63 (67.0) 45 (84.9) 0.03 44 (64.7) 64 (81.0) 0.01 56 52 22.12 10.92 39.08 (83.6) (65.0) (3.82) (2.10) (7.64) P-valueb<0.001 0.05 0.a Among patients with no history of taking CYC. bSignificance level of the w2 (or Fisher's exact) statistic for categorical variables and two-tailed t-test (or Wilcoxon's rank sum test) for continuous variables.www.rheumatology.oxfordjournals.orgTreatment preferences in lupusTABLE 5 Logistic regression of willingness to receive CYC, with serial addition of sociodemographic variables, clinical context, personality traits and other patient beliefsaVariable, OR (95 CI) Race/ethnicity White African-American Incomeb Insurance Without private With private Marital status Not married Married Depression, CES-Dc Quartile 1 Quartile 2 Quartile 3 Quartile 4 Prayer efficacy No help Some help Much help Internal HLCc Quartile 1 Quartile 2 Quartile 3 Quartile 4 Perceived effectivenessb,c Trust in physiciansc Quartile 1 Quartile 2 Quartile 3 QuartileaModelModelModelModel1.00 0.36 (0.15, 0.86)1.00 0.32 (0.10, 1.00) 0.98 (0.59, 1.61) 1.00 1.50 (0.45, 4.97) 1.00 1.42 (0.57, 3.54)1.00 0.26 (0.08, 0.91) 1.11 (0.64, 1.93) 1.00 1.50 (0.42, 5.34) 1.00 1.34 (0.50, 3.61) 1.00 1.97 (0.63, 6.17) 5.73 (1.30, 25.17) 1.87 (0.48, 7.25) 1.00 0.94 (0.14, 6.45) 1.29 (0.19, 8.59) 1.00 1.04 (0.35, 3.08) 1.52 (0.43, 5.33) 3.09 (0.83, 11.52)1.00 0.27 (0.06, 1.26) 1.19 (0.60, 2.37) 1.00 1.27 (0.30, 5.43) 1.00 1.37(0.33, 5.59) 1.00 3.43 (0.78, 15.09) 9.83 (1.28, 75.25) 2.59 (0.41, 16.35) 1.00 0.61 (0.06, 6.23) 0.58 (0.06, 5.72) 1.00 0.79 1.47 1.68 1.(0.18, (0.30, (0.31, (1.23,3.38) 7.18) 9.10) 1.75)1.00 8.97 (1.85, 43.46) 1.66 (0.36, 7.68) 3.00 (0.59, 15.30)Among patients with no history of taking CYC. bPer unit difference. cHigher score indicates more of the concept being measured. HLC: health locus of control.Trust in physicians appears to be a more relevant factor in SLE patients' treatment preferences for CYC than race/ ethnicity. The significance of patient trust in physicians in determining patient preferences has been observed in other studies. In a study of Hispanic, African-American and white patients with knee OA, physician trust was a major determinant of racial and ethnic variation in joint replacement consideration by patients [9]. In a study of cardiac patients, patient level of medical mistrust was an independent predictor of patient satisfaction [17], which has been linked with patient compliance and utilization of health services [5]. Similarly, in a study of AfricanAmericans' perceptions of breast cancer treatment, mistrust of the medical establishment was a significant concern [24]. Racial/ethnic variations in treatment prefer.
